Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience
Authors:
Open Access
- 14 May 2025
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (6) , 1-13
Abstract
Introduction: Ravulizumab, a monoclonal antibody targeting C5, was recently approved for the treatment of anti-AChR positive generalized myasthenia gravis (gMG) patients. The objective of this study is to present the Italian multicenter real-world experience evaluating the safety and efficacy of ravulizumab in gMG within the context of the Expanded Early Access Program (EAP). Methods: We conducted a retrospective study in 7 gMG referral centres in Italy. Demographic and clinical characteristics were recorded at baseline and during follow-up through clinical scale changes including Myasthenia Gravis-Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis Composite (MGC). Frequency of minimal symptom expression (MSE) and changes in concomitant medications were also evaluated. Results: Twenty-four gMG patients (10/24 females) aged between 24 and 82 years (Median 60.5, IQR 52.5–67.5), were included. Fifteen patients had undergone thymectomy, and 14 had a thymoma. Median follow-up duration was 26 weeks (range 10–74, IQR 26–42). MG-ADL and QMG scores showed a significant decrease with respect to baseline (p < 0.001). MSE was achieved by 37.5% patients at the last available follow-up. Tapering of prednisone daily dosage was possible in 76% of patients. Thymoma was significantly associated with QMG score reduction and the frequency of QMG responders at week 2 (p = 0.03). Three patients discontinued treatment. One patient experienced a myasthenic exacerbation and needed rescue therapy. Infectious adverse events were reported in 5/24 patients, and a Stevens-Johnson syndrome in one patient. Conclusions: Real-world data confirm the effectiveness, safety, and prednisone-sparing effect of ravulizumab in patients with gMG, especially in those with thymoma.Keywords
Funding Information
- Università degli Studi di Roma La Sapienza
This publication has 33 references indexed in Scilit:
- Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trialThe Lancet Neurology, 2019
- Myasthenia gravis: the role of complement at the neuromuscular junctionAnnals of the New York Academy of Sciences, 2017
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyThe Lancet Neurology, 2017
- Surface complement C3 fragments and cellular binding of microparticles in patients with SLELupus Science & Medicine, 2017
- Randomized Trial of Thymectomy in Myasthenia GravisNew England Journal of Medicine, 2016
- The MG CompositeNeurology, 2010
- Correlation of C3 level with severity of generalized myasthenia gravisMuscle & Nerve, 2009
- Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validityNeurology, 2005
- Myasthenia gravis activities of daily living profileNeurology, 1999
- Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptorEuropean Journal of Immunology, 1992